New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:54 EDTISISNEJM publishes study on loss-of-function mutations in APOC3
An article in the New England Journal of Medicine concluded, "Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease." Isis Pharmaceuticals is advancing an APOC3 antisense program into Phase 3, says Piper Jaffray. The firm believes the NEJM article further supports a role for the product beyond the pancreatitis-lowering benefit. Reference Link]:[http://www.nejm.org/doi/full/10.1056/NEJMoa1307095?query=featured_home]
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ISIS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use